StockNews.com upgraded shares of Seres Therapeutics (NASDAQ:MCRB – Get Rating) from a sell rating to a hold rating in a research note issued to investors on Thursday. A number of other equities analysts also recently weighed in on the company. JPMorgan Chase & Co. initiated coverage on Seres Therapeutics in a research report on Friday, […]
Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 12,180,000 shares, a growth of 36.1% from the April 15th total of 8,950,000 shares. Based on an average daily volume of 2,480,000 shares, the days-to-cover ratio is […]
Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) saw a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 12,180,000 shares, a growth of 36.1% from the April 15th total of 8,950,000 shares. Based on an average trading volume of 2,480,000 shares, the days-to-cover ratio is […]
Sutro Biopharma (NASDAQ:STRO – Get Rating) and Moderna (NASDAQ:MRNA – Get Rating) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation. Insider & Institutional Ownership 87.6% of Sutro Biopharma shares are owned […]
Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Rating) – Equities researchers at Chardan Capital issued their FY2024 earnings per share estimates for shares of Seres Therapeutics in a research report issued to clients and investors on Wednesday, May 10th. Chardan Capital analyst K. Nakae anticipates that the biotechnology company will post earnings per share of ($1.49) […]